US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Aprea presents preclinical data at AACR - Strong synergistic effect with APR-246 and cisplatin

STOCKHOLM – April 9, 2013. Aprea AB today presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA. The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds. Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.The title of Aprea’s poster presentation at AACR was “Strong synergistic effects with cisplatin and APR-246, a novel compound

Aprea to present at the American Association for Cancer Research (AACR) annual meeting in Washington, DC, in April 2013

STOCKHOLM – April 3, 2013. Aprea AB today announces that a poster entitled “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients” will be presented at the upcoming AACR meeting in Washington, DC, USA, in April 2013. Aprea is a Karolinska Development portfolio company.The poster contains data from preclinical combination studies with APR-246 and platinum compounds. The presentation will take place on Tuesday April 9 between 8.00 AM and 12.00 PM (EST) at the AACR meeting at the Walter E.

Aprea announces positive data from a clinical Phase I/II study with APR-246 in patients with advanced cancers

STOCKHOLM – September 18, 2012. Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology. Based on the positive data, Aprea is planning to advance APR-246 into a Phase II proof-of-concept study in ovarian cancer. Aprea is a Karolinska Development portfolio company.In the Phase I/II-trial, escalating doses of APR-246 were administered as monotherapy to 22 patients with advanced blood- or prostate cancer during up to four consecutive days. Dose

There are no items matching the current filter
There are no more items matching the current filter
Back to top